pretickt

Is SYK a good stock to buy?

Stryker Corporation · end-of-day data as of Nov 13, 2026

Stryker
SYK · $118B
$309.64-0.9%
Nov 13, 2026 · close
$300SepOctNov9:3016:003 months -6.3%Nov 13 · close
▲ 5
  • PT$365.59 +18.1%
  • ConsensusBuy · 31
  • Trendbullish
  • MA20×50Golden 10d ago
  • Sector▲ +15.9%
Neutral
  • Earnings in83d
  • P/E33.0x
  • RSI51
  • Support-5.8%
  • Resistance+0.2%
  • Off 52w high-20.5%
  • Volume1.0x
  • Bollingerlower half
  • News0.00
  • FCF yield+3.9%
  • P/E vs own-7.0%
  • P/E vs sector+2.4%
  • 52w range$267–$389
  • ATR+3.6%
  • Off ATH-23.8%
▼ 3
  • Insiders-$297M
  • MAs1 of 4
  • MACD-0.80

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Stryker a good stock to buy?

Stryker is strong on 3 of the 5 questions about the business. The price is low: 33.0 times its earnings, below its 3-year median of 39.8 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage some edge
  3. Economics profits growing
  4. Execution mixed
  5. Fragility sturdy
  6. Price below its usual
DemandDo people want more of what it sells?growing

SYK sales growth revenue growth

+11%a year, for the last 3 years

Stryker's sales grew 11% a year for 3 years, to $25.12B in fiscal 2025.

SYK analysts' forecast revenue estimates

+7%the sales they expect next fiscal year, on the last

Analysts expect Stryker's sales to grow 7% to $26.82B in fiscal 2026 (20 analysts).

SYK competitors

pretickt analysis+8%its sales in 12 months, on a year before

Stryker's sales grew 8% in the 12 months to Sep 30, 2026, slower than Edwards Lifesciences (+13%), Abbott (+10%) and Boston Scientific (+9%).

SYK sales by business revenue by segment

62%of its sales from MedSurg

MedSurg brought Stryker 62% of its sales in fiscal 2025; Orthopaedics 38%.

Advantage moatIs it hard to copy?some edge

SYK margin on each sale gross margin

66%left after making the product

Stryker kept 66% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 70%.

EconomicsDoes it make good money?profits growing

SYK cash generated free cash flow

$4.57Bcash left after investing, last 12 months

Stryker generated $4.57B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

SYK profit per share

+8%in its last fiscal year

Stryker's earnings per share grew 8% in fiscal 2025, to $8.40.

ExecutionDoes it deliver what it promises?mixed

SYK earnings vs estimates

6 of 8quarters above the analysts' estimate

Stryker beat the analysts' profit estimate in 6 of its last 8 quarters, the latest on Oct 29, 2026.

SYK insider selling

-$580Msold, net, by its executives in 12 months

Stryker's executives and directors sold a net $580M of shares in the 12 months to Nov 13, 2026; none bought.

SYK number of employees

+6%more people in a year

Stryker had 56,000 employees at the end of fiscal 2025, 6% more than a year before.

Fragility risksCould something break it?sturdy

SYK financial health Altman Z-score

4.7Altman Z-score, safe above 3

Stryker's Altman Z-score is 4.7 (Nov 13, 2026), above 3, where the safe zone starts.

SYK quality checks Piotroski score

9 of 9checks passed

Stryker passes all 9 Piotroski checks in the 12 months to Sep 30, 2026.

SYK shareholders institutional ownership

pretickt analysis
  • Vanguard8.0% ▼
  • BlackRock7.1% ▼
  • JPMorgan4.5% ▲
2,341institutions hold it; the largest sold shares

2,341 institutions hold 81% of Stryker's shares (Jun 30, 2026); JPMorgan added shares that quarter, Vanguard and BlackRock sold some.

SYK in past recessions

pretickt analysis-4%its sales in the worst one

Stryker's sales fell in 1 of the last 2 US recessions, by as much as 4% in fiscal 2020.

Price valuationIs the price reasonable?below its usual

SYK price vs profit P/E ratio

33.0×a year's earnings

Stryker's P/E ratio is 33.0 (Nov 13, 2026), below its 3-year median of 39.8.

SYK price vs competitors

pretickt analysis33.0×a year's earnings, against its competitors

Investors pay 33.0 times Stryker's earnings (Nov 13, 2026), more than for Boston Scientific (18.8), less than for Edwards Lifesciences (60.5) and Abbott (40.2).

SYK analysts' target price target

+18%to their average target

Analysts' average price target for Stryker is $366, 18% above the Nov 13, 2026 close of $309.64.

SYK analyst ratings, 90 days

pretickt analysis
  • Canaccord Genuitydowngrade
0 up, 1 downratings raised and cut

In the 90 days to Nov 13, 2026, Canaccord Genuity downgraded Stryker.

SYK growth priced in fair value

pretickt analysis+10%a year, for ten years, to be worth the price

At $309.64 a share, Stryker's free cash flow must grow about 10% a year for ten years to be worth the price (Nov 13, 2026).

What is Stryker's P/E ratio?

Stryker's P/E ratio is 33.0 (Nov 13, 2026), below its 3-year median of 39.8. Investors pay 33.0 times Stryker's earnings (Nov 13, 2026), more than for Boston Scientific (18.8), less than for Edwards Lifesciences (60.5) and Abbott (40.2).

Who are Stryker's biggest competitors?

pretickt compares Stryker with Medtronic, Abbott, Boston Scientific and Edwards Lifesciences. Stryker's sales grew 8% in the 12 months to Sep 30, 2026, slower than Edwards Lifesciences (+13%), Abbott (+10%) and Boston Scientific (+9%).

Are insiders selling Stryker stock?

Stryker's executives and directors sold a net $580M of shares in the 12 months to Nov 13, 2026; none bought.

How does Stryker make money?

MedSurg brought Stryker 62% of its sales in fiscal 2025; Orthopaedics 38%.

Who owns Stryker stock?

2,341 institutions hold 81% of Stryker's shares (Jun 30, 2026); JPMorgan added shares that quarter, Vanguard and BlackRock sold some.

How many employees does Stryker have?

Stryker had 56,000 employees at the end of fiscal 2025, 6% more than a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.